https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%B3%BD%E7%8F%82
泽珂 - 版本历史
2026-04-18T06:34:33Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%B3%BD%E7%8F%82&diff=313538&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T07:00:29Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[泽珂]]([[Zytiga]])</strong>，通用名为<strong>[[醋酸阿比特龙]]([[Abiraterone Acetate]])</strong>，研发代码为<strong>[[CB7598]]</strong>，是由[[强生]]([[Johnson & Johnson]])旗下[[杨森制药]]([[Janssen]])研发的一种口服、选择性、不可逆的<strong>[[CYP17抑制剂]]</strong>。作为前列腺癌内分泌治疗的里程碑药物，[[泽珂]]通过阻断睾丸、肾上腺及肿瘤微环境中的雄激素生物合成，在2026年的诊疗体系中仍是<strong>[[转移性激素敏感性前列腺癌]]([[mHSPC]])</strong>及<strong>[[转移性去势抵抗性前列腺癌]]([[mCRPC]])</strong>的标准方案。该药必须与<strong>[[泼尼松]]</strong>（或[[泼尼松龙]]）联用，以平衡其引起的盐皮质激素过量副作用。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">泽珂 (Zytiga)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Abiraterone·阿比特龙·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Abiraterone Acetate molecular structure targeting CYP17A1</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[CYP17A1]] 酶</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1581([[CYP17A1]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2603</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P05093</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">349.5g/mol</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">标准剂量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">1000mg QD (空腹)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">必配药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">泼尼松 5mg BID</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026热点</th><br />
<td style="padding: 12px; color: #1e40af;">联合PARPi一线强化治疗</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多源性雄激素阻断</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[泽珂]]通过不可逆地抑制<strong>[[CYP17]]</strong>（17α-羟化酶和17,20-裂解酶）发挥药效，这一酶复合体是雄激素合成通路的关键节点。其2026年药理学研究将其特点概括为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>切断剩余雄激素来源：</strong> 传统去势（[[ADT]]）仅能抑制睾丸来源的雄激素，而[[泽珂]]能进一步阻断肾上腺及肿瘤病灶自身（自分泌）产生的雄激素，将体内雄激素水平降至“极致”。</li><br />
<li style="margin-bottom: 12px;"><strong>泼尼松的必要代偿：</strong> 抑制[[CYP17]]会导致[[皮质醇]]水平下降，引发反馈性[[ACTH]]升高，从而引起[[盐皮质激素]]蓄积。联用<strong>[[泼尼松]]</strong>可补充糖皮质激素并抑制ACTH，预防高血压及低钾血症。</li><br />
<li style="margin-bottom: 12px;"><strong>克服 AR 通路激活：</strong> 2026年分子模型显示，[[泽珂]]能有效应对因雄激素前体物质代偿性上调引发的<strong>[[去势抵抗]]</strong>进程。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据与获益矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评价)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键获益数据</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[LATITUDE]]研究</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">高危[[mHSPC]]患者；联合[[ADT]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>死亡风险降低 38%</strong>；显著延长中位[[OS]]。确立一线强化标准。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[COU-AA-302]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">化疗前[[mCRPC]]；联合[[泼尼松]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>rPFS 显著延长</strong>；推迟化疗开始时间达 8.4个月。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[PROpel]]研究</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">一线[[mCRPC]]；泽珂+[[奥拉帕利]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026长程随访：针对[[HRR]]突变亚组展现出颠覆性获益。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：从早期联合到精准代谢监控</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[泽珂]]在2026年的临床路径强调“获益前置”与“代谢安全性全流程监测”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>mHSPC 的早期打击：</strong> 2026版[[NCCN]]明确建议：针对高瘤负荷[[mHSPC]]，应尽早启用<strong>[[ADT]]+[[泽珂]]+[[泼尼松]]</strong>。相比传统方案，其能显著推迟影像学进展，并为后续二线治疗预留更大的时间窗口。</li><br />
<li style="margin-bottom: 12px;"><strong>肝毒性与心血管监护：</strong> 2026管理规范要求：服药首月需每两周监测一次<strong>[[肝功能]]</strong>（[[ALT]]/[[AST]]）。针对有基础心脏病的老年患者，需严密监控血钾水平，防止[[低钾]]诱发心律失常。</li><br />
<li style="margin-bottom: 12px;"><strong>空腹服药的严格执行：</strong> 2026年药师共识强调：因食物可导致[[阿比特龙]]血药浓度波动达 10倍以上，必须坚持<strong>[[空腹服药]]</strong>（服药前2小时及服药后1小时不进食）以确保安全性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CYP17A1]]：</strong> 驱动雄激素生物合成的核心酶，[[泽珂]]的药理靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[mCRPC]]：</strong> 转移性去势抵抗性前列腺癌，泽珂最早成名的应用领域。</li><br />
<li style="margin-bottom: 8px;"><strong>[[盐皮质激素副作用]]：</strong> 包括高血压、水肿及低钾血症，是[[泽珂]]需重点防范的风险。</li><br />
<li style="margin-bottom: 8px;"><strong>[[奥拉帕利]]：</strong> 2026年常与[[泽珂]]形成联合方案的[[PARP]]抑制剂。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Fizazi K, et al. (2017/2026Update).</strong> <em>Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项基石研究确立了阿比特龙在mHSPC阶段的统治级地位，是内分泌治疗前置的标志性成果。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Saad F, et al. (2023/2026Revision).</strong> <em>Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROpel Trial).</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年数据确认，联合疗法在基因筛查指导下，显着提升了晚期前列腺癌患者的一线获益深度。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
泽珂 (Zytiga) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CYP17A1]]•[[ACTH]]•[[DHEA]]•[[Pregnenolone]]•[[CYP3A4]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">联合药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[泼尼松]]•[[奥拉帕利]]•[[多西他赛]]•[[瑞卢戈利]]•[[恩扎卢胺]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Janssen]]•[[强生]]•[[SinoCellGene协作]]•[[FDA]]•[[NCCN]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿领域</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CYP17阻断与ARi序贯]]•[[HRR突变协同]]•[[肝毒性分子预警]]•[[三联治疗模式]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166